IN THE CLAIMS:

Claim 1 (**currently amended**): A method for the treatment or prophylaxis of a disease or medical condition wherein inhibition of carboxypepsidase U is beneficial, said method comprising administering to a warm-blooded animal in need thereof an effective amount~~The use~~ of a compound of formula (I):



(I)

wherein:

X is $(CH_2)_mY(CH_2)_n$;

m and n are, independently, 1, 2, 3, 4, 5 or 6; provided that m + n is not more than 6;

Y is a bond, O, $S(O)_p$, or S-S;

R^1 is CO_2R^{15} or a carboxylic acid isostere ~~such as $S(O)_2OH$, $S(O)_2NHR^{15}$, $PO(OR^{15})OH$, $PO(OR^{15})NH_2$, $B(OR^{15})_2$, $PO(R^{15})OH$, $PO(R^{15})NH_2$ or tetrazole~~;

R^2, R^3, R^4, R^5 and R^6 are, independently, hydrogen, C_{1-6} alkyl (optionally substituted by halogen, hydroxy, cyano, SH, $S(O)_3H$, $S(O)_q(C_{1-6}$ alkyl), $OC(O)(C_{1-4}$ alkyl), CF_3, C_{1-4} alkoxy, OCF_3, COOH, $CONH_2$, $CONH(C_{1-6}$ alkyl), NH_2, $CNH(NH_2)$, or $NHCNH(NH_2)$), C_{3-6} cycloalkyl(C_{1-4})alkyl (wherein the cycloalkyl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$), heterocyclyl(C_{1-4})alkyl (wherein the heterocyclyl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$), phenyl(C_{1-4})alkyl (wherein the phenyl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$) or heteroaryl(C_{1-4})alkyl (wherein the heteroaryl ring is

optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$);

p and q are, independently, 0, 1 or 2;

R^7, R^8, R^9, R^{10}, R^{11}, R^{12} and R^{13} are, independently, H or C_{1-4} alkyl;

R^{14} is H or C_{1-4} alkyl; and,

R^{15} is H or C_{1-4} alkyl;

or a pharmaceutically acceptable salt thereof. ~~or solvate thereof, or a solvate of such a salt; in a method of manufacturing a medicament for the treatment or prophylaxis of a condition wherein inhibition of carboxypeptidase U is beneficial~~.

Claim 2 (**currently amended**): A compound of formula (I):



(I)

wherein:

X is $(CH_2)_4$;

R^1 is CO_2R^{15};

R^2 is C_{1-6} alkyl, benzyl, straight-chain C_{1-6} alkyl substituted at its terminus by NH_2, $CNH(NH_2)$, ~~or~~ $NHCNH(NH_2)$ or (6-aminopyridin-3-yl)methyl; C_{3-6} cycloalkyl substituted by NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; heterocyclyl containing at least one nitrogen atom; non-nitrogen containing heterocyclyl substituted with NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; heteroaryl substituted with NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; phenyl substituted with NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; heteroaryl(C_{1-4})alkyl substituted with NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; phenyl(C_{1-4})alkyl substituted with NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; or C_{3-6} cycloalkyl(C_{1-4})alkyl substituted with NH_2,

$CNH(NH_2)$ or $NHCNH(NH_2)$; all of the above rings being optionally further substituted by one or more of: halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy or OCF_3;

one of R^3, R^4, R^5 and R^6 is independently, hydrogen, heteroaryl(C_{1-4})alkyl (wherein the heteroaryl ring is optionally substituted by one or more of halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$); and the others are, independently, hydrogen, C_{1-6} alkyl (optionally substituted by halogen, hydroxy, cyano, SH, $S(O)_3H$, $S(O)_q(C_{1-6}$ alkyl), $OC(O)(C_{1-4}$ alkyl), CF_3, C_{1-4} alkoxy, OCF_3, COOH, $CONH_2$, $CONH(C_{1-6}$ alkyl), NH_2, $CNH(NH_2)$, or $NHCNH(NH_2)$), C_{3-6} cycloalkyl(C_{1-4})alkyl (wherein the cycloalkyl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$), heterocyclyl(C_{1-4})alkyl (wherein the heterocyclyl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$), phenyl(C_{1-4})alkyl (wherein the phenyl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$) or heteroaryl(C_{1-4})alkyl (wherein the heteroaryl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$);

p and q are, independently, 0, 1 or 2;

R^7, R^8, R^9, R^{10}, R^{11}, R^{12} and R^{13} are, independently, H or C_{1-4} alkyl;

R^{14} is H or C_{1-4} alkyl; and,

R^{15} is H or C_{1-4} alkyl;

or a pharmaceutically acceptable salt thereof ~~or solvate thereof, or a solvate of such a salt~~.

Claim 3 (**currently amended**): ~~A~~ The compound of formula (I) ~~or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.~~ as claimed in claim 2 wherein:

X is $(CH_2)_4$;

R^1 is CO_2R^{15};

R^2 is straight-chain C_{1-6} alkyl substituted at its terminus by NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; C_{3-6} cycloalkyl substituted by NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; heterocyclyl containing at least one nitrogen atom; non-nitrogen containing heterocyclyl substituted with NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; heteroaryl substituted with NH_2,

$CNH(NH_2)$ or $NHCNH(NH_2)$; phenyl substituted with NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; heteroaryl(C_{1-4})alkyl substituted with NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; phenyl(C_{1-4})alkyl substituted with NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; or C_{3-6} cycloalkyl(C_{1-4})alkyl substituted with NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; all of the above rings being optionally further substituted by one or more of: halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy or OCF_3;

one of R^3, R^4, R^5 and R^6 is independently, hydrogen, heteroaryl(C_{1-4})alkyl (wherein the heteroaryl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$); and the others are, independently, hydrogen, C_{1-6} alkyl (optionally substituted by halogen, hydroxy, cyano, SH, $S(O)_3H$, $S(O)_q(C_{1-6}$ alkyl), $OC(O)(C_{1-4}$ alkyl), CF_3, C_{1-4} alkoxy, OCF_3, COOH, $CONH_2$, $CONH(C_{1-6}$ alkyl), NH_2, $CNH(NH_2)$, or $NHCNH(NH_2)$), C_{3-6} cycloalkyl(C_{1-4})alkyl (wherein the cycloalkyl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$), heterocyclyl(C_{1-4})alkyl (wherein the heterocyclyl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$), phenyl(C_{1-4})alkyl (wherein the phenyl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$) or heteroaryl(C_{1-4})alkyl (wherein the heteroaryl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3, C_{1-4} alkoxy, OCF_3, NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$);

p and q are, independently, 0, 1 or 2;

R^7, R^8, R^9, R^{10}, R^{11}, R^{12} and R^{13} are, independently, H or C_{1-4} alkyl;

R^{14} is H or C_{1-4} alkyl; and,

R^{15} is H or C_{1-4} alkyl;

or a pharmaceutically acceptable salt thereof ~~or solvate thereof, or a solvate of such a salt~~.

Claim 4 (**currently amended**): ~~A~~ The compound of formula (I) ~~or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt~~ as claimed in claim 2 ~~or 3~~ wherein:

R^1 is CO_2R^{15};

R^2 is straight-chain C_{1-6} alkyl substituted at its terminus by NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; C_4 alkyl ~~(such as $CH(CH_3)CH_2CH_3$ or $CH_2CH(CH_3)_2$)~~; or (aminopyridinyl)methyl ~~(for example (6-aminopyridin-3-yl)methyl)~~;

one of R^3 and R^4 is (indol-3-yl)CH_2 optionally substituted by halo or hydroxy; and the other is benzyl (optionally substituted by halo or hydroxy) or C_4 alkyl ~~(such as $CH(CH_3)CH_2CH_3$ or $CH_2CH(CH_3)_2$)~~;

or R^3 and R^4 are both methyl;

R^5 and R^6 are, independently, C_{1-6} alkyl ~~(for example CH_3, $CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$ or $CH_2CH(CH_3)_2$)~~;

R^7, R^8, R^9, R^{11}, R^{12}, R^{13} and R^{14} are H;

R^{10} is C_{1-4} alkyl; and,

R^{15} is H or C_{1-4} alkyl;

or a pharmaceutically acceptable salt thereof.

Claim 5 (**currently amended**): The method of claim 1 ~~A compound as claimed in any one of claims 2 to 4~~ wherein X is $(CH_2)_4$.

Claim 6 (**currently amended**): The method of claim 1 ~~A compound as claimed in any one of claims 2 to 5~~ wherein R^1 is CO_2R^{15} in which R^{15} is H or C_{1-4} alkyl.

Claim 7 (**currently amended**): ~~A~~ The compound as claimed in claim 2 ~~any one of claims 2 to 6~~ wherein R^2 is straight-chain C_{1-6} alkyl substituted at its terminus by NH_2, $CNH(NH_2)$ or $NHCNH(NH_2)$; C_4 alkyl ~~(such as $CH(CH_3)CH_2CH_3$ or $CH_2CH(CH_3)_2$)~~; or (aminopyridinyl)methyl.

Claim 8 (**currently amended**): ~~A~~ The compound as claimed in claim 2 ~~any one of claims 2 to 4~~ wherein R^2 is C_{1-6} alkyl ~~($CH(CH_3)CH_2CH_3$ or $CH_2CH(CH_3)_2$)~~, benzyl, or straight-chain C_{1-6} alkyl substituted at its terminus by NH_2, $CNH(NH_2)$, $NHCNH(NH_2)$ or (6-aminopyridin-3-yl)methyl.

Claim 9 (**currently amended**): ~~A~~ The compound as claimed in claim 2 ~~any one of claims 2 to 8~~ wherein R^2 is straight-chain C_{1-6} alkyl substituted at its terminus by NH_2, $CNH(NH_2)$, $NHCNH(NH_2)$ or (6-aminopyridin-3-yl)methyl.

Claim 10 (**currently amended**): ~~A~~ The compound as claimed in claim 2 ~~any one of claims 2 to~~ wherein R^3 is CH_2indolyl, ~~(~~wherein the indolyl is optionally substituted by one or more of: halogen or hydroxy, C_{1-4} alkyl or benzyl (optionally substituted by halogen or hydroxy).

Claim 11 (**currently amended**): ~~A~~ The compound as claimed in claim 2 ~~any one of claims 2 to 10~~ wherein R^4 is CH_2indolyl, ~~(~~wherein the indolyl is optionally substituted by one or more of: halogen or hydroxy, C_{1-6} alkyl ~~($CH(CH_3)CH_2CH_3$ or $CH_2CH(CH_3)_2$)~~ or benzyl (optionally substituted by halogen or hydroxy).

Claim 12 (**currently amended**): ~~A~~ The compound as claimed in claim 2 ~~any one of claims 2 to 11~~ wherein R^5 and R^6 are, independently, C_{1-6} alkyl ~~(such as methyl, iso-propyl, $CH(CH_3)CH_2CH_3$ or $CH_2CH(CH_3)_2$)~~.

Claim 13 (**currently amended**): ~~A~~ The compound as claimed in claim 2 ~~any one of claims 2 to 12~~ wherein R^7, R^8, R^9, R^{11}, R^{12}, R^{13} and R^{14} are all H.

Claim 14 (**currently amended**): ~~A~~ The compound as claimed in claim 2 ~~any one of claims 2 to 4~~ wherein R^{10} is C_{1-4} alkyl.

Claim 15 (**currently amended**): ~~A~~ The compound as claimed in claim 2 which is a compound of the following formula



in which

$\mathbf{R^{3a}}$ is H, $\mathbf{R^{3b}}$ is H and $\mathbf{R^{15}}$ is H;

$\mathbf{R^{3a}}$ is OH, $\mathbf{R^{3b}}$ is Cl and $\mathbf{R^{15}}$ is H;

$\mathbf{R^{3a}}$ is OH, $\mathbf{R^{3b}}$ is Cl and $\mathbf{R^{15}}$ **is** CH_3;

$\mathbf{R^{3a}}$ is H, $\mathbf{R^{3b}}$ is H and $\mathbf{R^{15}}$ **is** CH_3;

$\mathbf{R^{3a}}$ is H, $\mathbf{R^{3b}}$ is Cl and $\mathbf{R^{15}}$ is H;























or



or a pharmaceutically acceptable salt thereof ~~or solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof~~.

Claim 16 (**currently amended**): A method for the treatment or prophylaxis of a disease or medical condition wherein inhibition of carboxypepsidase U is beneficial, said method comprising administering to a warm-blooded animal in need thereof an effective amount ~~The use~~ of a compound of formula (I) or a pharmaceutically acceptable salt thereof ~~or solvate thereof, or a solvate of such a salt;~~ as claimed in claim 2 ~~any one of claims 2 to 15 in a method of manufacturing a medicament for the treatment or prophylaxis of a condition wherein inhibition of carboxypeptidase U is beneficial~~.

Claim 17 (**currently amended**): The method ~~use~~ as claimed in claim 16 wherein said disease or medical condition is selected from ~~for the manufacture of a medicament for the treatment or prophylaxis of~~ thrombosis and/or hypercoagulability in blood and/or tissues; atherosclerosis; fibrotic conditions; inflammatory diseases; or a condition which benefits from maintaining or enhancing bradykinin levels in the body of a mammal ~~(such as man)~~.

Claim 18 (**currently amended**): A pharmaceutical formulation comprising ~~containing~~ a compound of formula (I) or a pharmaceutically acceptable salt thereof ~~or solvate thereof, or a solvate of such a salt~~; as claimed in claim 2 ~~any one of claims 2 to 15~~ as active ingredient in combination with a pharmaceutically acceptable adjuvant, diluent or carrier.

Claim 19 (**currently amended**): A compound of formula



(VII)

wherein R^3 to R^{12} and X are as defined in claim 2 ~~any one of claims 1 to 14~~.

Claim 20 (**currently amended**): A process for preparing a compound as claimed in claim 19 which comprises treating a compound of formula VI ~~in which PG1 is a suitable protecting group with a peptide coupling agent in the presence of a non-nucleophilic base in a polar aprotic solvent and then removing the protecting group.~~



(VI)

in which PG^1 is a suitable protecting group with a peptide coupling agent in the presence of a non-nucleophilic base in a polar aprotic solvent and then removing the protecting group.

Claim 21 (**currently amended**): A process for preparing a compound of formula I as claimed in claim 2 ~~any one of claims 2 to 17~~ which comprises reacting a compound of formula VII as defined in claim 19 with a compound of formula VIII



(VIII)

in which Y is an activated ester or NY is an isocyanate group.

Claim 22 (**new**): The method as claimed in claim 1 wherein said disease or medical condition is selected from thrombosis and/or hypercoagulability in blood and/or tissues; atherosclerosis; fibrotic conditions; inflammatory diseases; or a condition which benefits from maintaining or enhancing bradykinin levels in the body of a mammal.